(Q45113880)

English

Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

scientific article published in December 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Kevin J Anstrom

1

object named as

Kevin J Anstrom

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

2

object named as

Shelby D Reed

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

author name string

Andrew S Allen

3

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

G Alastair Glendenning

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Kevin A Schulman

5

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

language of work or name

0 references

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

101

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

2584-2592

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20674

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20674

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45113880&oldid=2066276222"